Production Options for Psilocybin: Making of the Magic
Janis Fricke, Claudius Lenz, Jonas Wick, Felix Blei, Dirk Hoffmeister
Chemistry - A European Journal July 16, 2018 DOI: 10.1002/chem.201802758 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Hallucinogen Pharmacology |
| Citations | 52 |
| Key findings | Psilocybin is a valuable candidate for development into a medication against depression and anxiety, and its biosynthesis has been recently elucidated, enabling biotechnological production. |
Abstract
Abstract The fungal genus Psilocybe and other genera comprise numerous mushroom species that biosynthesize psilocybin (4‐phosphoryloxy‐ N , N ‐dimethyltryptamine). It represents the prodrug to its dephosphorylated psychotropic analogue, psilocin. The colloquial term “magic mushrooms” for these fungi alludes to their hallucinogenic effects and to their use as recreational drugs. However, clinical trials have recognized psilocybin as a valuable candidate to be developed into a medication against depression and anxiety. We here highlight its recently elucidated biosynthesis, the concurrently developed concept of enzymatic in vitro and heterologous in vivo production, along with previous synthetic routes. The prospect of psilocybin as a promising therapeutic may entail an increased demand, which can be met by biotechnological production. Therefore, we also briefly touch on psilocybin's therapeutic relevance and pharmacology.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |
Citations in the library
Cited by 36
- The Therapeutic Potential of Psilocybin Molecules May 15, 2021
- Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives Metabolic Engineering March 26, 2020
- Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. Fungal biology April 1, 2022
- In vivo production of psilocybin in E. coli Metabolic Engineering September 21, 2019
- Simultaneous Production of Psilocybin and a Cocktail of β‐Carboline Monoamine Oxidase Inhibitors in “Magic” Mushrooms Chemistry - A European Journal November 14, 2019
and 31 more in the library
Cites 18
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- The pharmacology of psilocybin Addiction Biology October 1, 2002
- Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study Psychopharmacology March 1, 2004
- Potential Therapeutic Effects of Psilocybin. Neurotherapeutics July 1, 2017
- Psilocybin – Summary of knowledge and new perspectives European Neuropsychopharmacology December 17, 2013
and 13 more in the library